Finally, in a prospective case–control study including HCC patients, the tumor mutational burden (TMB), which has often been reported to serve as a biomarker for immunotherapy response in various cancers [65], was shown to be higher in ctDNA than tissue samples and to correlate with genomic alterations in HTERT and TP53 [66]. This evidence concerns the gene TP53 and neoplasm.